Tagged with Lilly

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster, Enhertu, among them; the launch of Novo’s Wegovy in China; Eli Lilly’s obesity partnership with Hong Kong-listed Laekna; Merck’s cancer…

Global With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk may lead the charge, but other contenders are looking to get a piece of this lucrative market as the two…

UK A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern Ireland’s potential post-Brexit drug shortages, and Oxford Biomedica’s reband as OXB.   UK to create world-first ‘early warning system’ for…

USA Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment pharma has already made to introducing AI in processes that range from drug discovery to marketing.   AI Leaders Eli…

China A roundup of some of the top stories coming out of China’s pharma industry, including AstraZeneca’s USD 1.92 billion deal with CSPC; Bayer’s new Shanghai incubator; Genentech’s purchase of Regor Pharmaceuticals’ breast cancer portfolio; Shanghai Fosun Pharmaceutical’s African manufacturing expansion, and CanSino’s USD 17 million polio vaccine grant from the…

Saudi Arabia Noncommunicable diseases are the leading cause of death and disability worldwide, accounting for 74 percent of all deaths and more than three out of four years lived with a disability. These chronic conditions – which cannot be transmitted from person to person and often require long-term or lifelong care –…

Hong Kong Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses the local impact of obesity, which affects 33 percent of the population, and the positive reimbursement outlook for newer treatments…

Saudi Arabia Attracting, developing, and retaining talented workers – both Saudi and foreign – is perhaps the key sticking point to Saudi Arabia achieving its ambitious transformation targets. Thus far this has involved both ‘carrot’ and ‘stick’ initiatives, ranging from tax incentives and specialised training programs on one side, to mandatory ‘Saudization’…

Saudi Arabia While international pharma has long been present in Saudi Arabia, the ambitious goals outlined in the country’s Vision 2030 economic transformation plan have encouraged companies to reinforce their commitment to the Kingdom. In recent PharmaBoardroom interviews, Saudi pharma country managers reveal their priorities and concerns.   Saudi Arabia holds immense…

Saudi Arabia With over 40 years of history in Saudi Arabia, in 2021 Eli Lilly moved to establish a regional headquarters in the country, underscoring its dedication to the country and region. Now led by Brazilian national Felipe Borges dos Reis, Lilly aims to tackle the pressing health concerns of diabetes and…

UK A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in Cambridge; the GBP 17.9 million initiative to boster UK clinical trials, and Obsidian Therapeutics’ USD 160.5 million Series C funding raise.…

USA Online pharmacies have still not captured a large share of the fragmented US pharma market, but Eli Lilly’s partnership with Amazon after a direct-sale initiative of its own may serve to shake up the establishment and show what a direct-to-consumer model can offer.   Eliminating the Middleman, or Not Amazon…